Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) have earned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $3.9375.

LUCD has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Finally, Ascendiant Capital Markets upped their price target on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a research report on Wednesday, December 10th.

Institutional Investors Weigh In On Lucid Diagnostics

Institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in Lucid Diagnostics during the 4th quarter worth approximately $246,000. Millennium Management LLC purchased a new stake in shares of Lucid Diagnostics during the fourth quarter valued at approximately $168,000. Abel Hall LLC bought a new position in shares of Lucid Diagnostics in the fourth quarter worth approximately $33,000. Squarepoint Ops LLC grew its holdings in shares of Lucid Diagnostics by 1,871.7% in the fourth quarter. Squarepoint Ops LLC now owns 342,883 shares of the company’s stock worth $374,000 after purchasing an additional 325,493 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of Lucid Diagnostics by 40.8% in the fourth quarter. Barclays PLC now owns 141,167 shares of the company’s stock worth $154,000 after buying an additional 40,891 shares during the period. 74.01% of the stock is currently owned by hedge funds and other institutional investors.

Lucid Diagnostics Stock Performance

LUCD stock opened at $1.25 on Tuesday. The company has a market capitalization of $172.10 million, a PE ratio of -1.20 and a beta of 1.18. Lucid Diagnostics has a one year low of $0.95 and a one year high of $1.80. The company’s 50 day moving average price is $1.30 and its two-hundred day moving average price is $1.18.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.